Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

FYX-051

 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

NitrilesPyridines

Narrower (1)

topiroxostat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
FYX-051: A Novel and Potent Hybrid-Type Inhibitor of Xanthine Oxidoreductase
4-[5-(Pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile (FYX-051) is a potent inhibitor of bovine milk xanthine… Expand
  • table 1
Is this relevant?
2011
2011
Establishment of simultaneous treatment model with citrate for preventing nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats
As a precedent study for elucidating the mechanism of possible urinary bladder carcinogenesis due to xanthine crystals induced by… Expand
Is this relevant?
2010
2010
Study on species differences in nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor
To clarify the toxicological aspects of FYX-051, a xanthine oxidoreductase inhibitor, which is currently being developed as a… Expand
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2009
2009
Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected].
Our previous study identified 2-[2-(2-methoxyethoxy)ethoxy]-5-[5-(2-methyl-4-pyridyl)-1H-[1,2,4] triazol-3-yl]benzonitrile (2… Expand
Is this relevant?
2009
2009
FYX-051, a Xanthine Oxidoreductase Inhibitor, Induces Nephropathy in Rats, but not in Monkeys
The present studies were performed to investigate the possible mechanism of marked species differences on nephropathy found in… Expand
  • table 1
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
2008
2008
Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051.
Xanthine oxidoreductase (XOR) catalyzes the reaction of hypoxanthine to xanthine and of xanthine to uric acid. Inhibitors of XOR… Expand
  • figure 3
Is this relevant?
2007
2007
Characterization of N-Glucuronidation of 4-(5-Pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): A New Xanthine Oxidoreductase Inhibitor
In humans, orally administered 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051) is excreted mainly as… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 6
  • figure 7
Is this relevant?
2006
2006
Metabolic Profile of FYX-051 (4-(5-Pyridin-4-yl-1H-[1,2,4]triazol-3-yl)pyridine-2-carbonitrile) in the Rat, Dog, Monkey, and Human: Identification of N-Glucuronides and N-Glucosides
FYX-051, 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl)pyridine-2-carbonitrile, is a novel xanthine oxidoreductase inhibitor that can… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2006
2006
Strain differences in the responsiveness between Sprague-Dawley and Fischer rats to nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor.
To determine a rat strain appropriate for carcinogenicity testing of FYX-051, a xanthine oxidoreductase inhibitor, we performed a… Expand
Is this relevant?
2005
2005
Simultaneous treatment with citrate prevents nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats.
The possible mechanism of the underlying nephropathy found in the rat toxicity study of FYX-051, a xanthine oxidoreductase… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE